Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems

被引:197
作者
Baryakova, Tsvetelina H. [1 ]
Pogostin, Brett H. [1 ]
Langer, Robert [2 ]
McHugh, Kevin J. [1 ,3 ]
机构
[1] Rice Univ, Dept Bioengn, Houston, TX 77005 USA
[2] MIT, David H Koch Inst Integrat Canc Res, Cambridge, MA USA
[3] Rice Univ, Dept Chem, Houston, TX 77005 USA
基金
美国国家卫生研究院; 美国国家科学基金会;
关键词
IONTOPHORETIC TRANSDERMAL SYSTEM; VACCINE SERIES COMPLETION; DISEASE-MODIFYING THERAPY; HUMAN GROWTH-HORMONE; QUALITY-OF-LIFE; MEDICATION ADHERENCE; DOSING FREQUENCY; ULCERATIVE-COLITIS; CARDIOVASCULAR-DISEASE; MULTIPLE-SCLEROSIS;
D O I
10.1038/s41573-023-00670-0
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Improving medication adherence is recognized as one of the most impactful and cost-effective strategies for improving the health of the general population. Here, Baryakova and colleagues assess the potential of next-generation drug delivery systems to mitigate many common impediments to adherence and discuss the impact that drug delivery systems have had across different disease types. Poor medication adherence is a pervasive issue with considerable health and socioeconomic consequences. Although the underlying reasons are generally understood, traditional intervention strategies rooted in patient-centric education and empowerment have proved to be prohibitively complex and/or ineffective. Formulating a pharmaceutical in a drug delivery system (DDS) is a promising alternative that can directly mitigate many common impediments to adherence, including frequent dosing, adverse effects and a delayed onset of action. Existing DDSs have already positively influenced patient acceptability and improved rates of adherence across various disease and intervention types. The next generation of systems have the potential to instate an even more radical paradigm shift by, for example, permitting oral delivery of biomacromolecules, allowing for autonomous dose regulation and enabling several doses to be mimicked with a single administration. Their success, however, is contingent on their ability to address the problems that have made DDSs unsuccessful in the past.
引用
收藏
页码:387 / 409
页数:23
相关论文
共 295 条
[61]   Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature [J].
Eek, Daniel ;
Krohe, Meaghan ;
Mazar, Iyar ;
Horsfield, Alison ;
Pompilus, Farrah ;
Friebe, Rachel ;
Shields, Alan L. .
PATIENT PREFERENCE AND ADHERENCE, 2016, 10 :1609-1621
[62]  
Ettinger Mark P, 2006, Endocr Pract, V12, P522
[63]   Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer [J].
Fallowfield, L ;
Atkins, L ;
Catt, S ;
Cox, A ;
Coxon, C ;
Langridge, C ;
Morris, R ;
Price, M .
ANNALS OF ONCOLOGY, 2006, 17 (02) :205-210
[64]  
FDA, 1999, DRUG APPR PACK NUTR
[65]   Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: A systematic review and meta-analysis [J].
Feagan, Brian G. ;
MacDonald, John K. .
INFLAMMATORY BOWEL DISEASES, 2012, 18 (09) :1785-1794
[66]  
Feuerstein A., 2015, THESTREET
[67]   Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. An analysis of initial phase II and III inhaled insulin (Exubera) trials and a two-year extension trial [J].
Fineberg, SE ;
Kawabata, T ;
Finco-Kent, D ;
Liu, C ;
Krasner, A .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (06) :3287-3294
[68]   Transzonular vitreous injection vs a single drop compounded topical pharmaceutical regimen after cataract surgery [J].
Fisher, Bret L. ;
Potvin, Rick .
CLINICAL OPHTHALMOLOGY, 2016, 10 :1297-1303
[69]   Hydroxyapatite-reinforced in situ forming PLGA systems for intraosseous injection [J].
Fisher, Paul D. ;
Venugopal, Ganesh ;
Milbrandt, Todd A. ;
Hilt, J. Zach ;
Puleo, David A. .
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A, 2015, 103 (07) :2365-2373
[70]   Once-Daily Dosing vs. Conventional Dosing Schedule of Mesalamine and Relapse of Quiescent Ulcerative Colitis: Systematic Review and Meta-Analysis [J].
Ford, Alexander C. ;
Khan, Khurram J. ;
Sandborn, William J. ;
Kane, Sunanda V. ;
Moayyedi, Paul .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 (12) :2070-2077